There is a consensus that portal venous pressure (PVP) modulation prevents portal hypertension (PHT) and consequent complications after adult-to-adult living donor liver transplantation (ALDLT). However, PVP-modulation strategies need to be updated based on the most recent findings. We examined our 10-year experience of PVP modulation and reevaluated whether it was necessary for all recipients or for selected recipients in ALDLT. In this retrospective study, 319 patients who underwent ALDLT from 2007 to 2016 were divided into 3 groups according to the necessity and results of PVP modulation: not indicated (n = 189), indicated and succeeded (n = 92), and indicated but failed (n = 38). Graft survival and associations with various clinical factors were investigated. PVP modulation was performed mainly by splenectomy to lower final PVP to ≤15 mm Hg. Successful PVP modulation improved prognosis to be equivalent to that of patients who did not need modulation, whereas failed modulation was associated with increased incidence of small-for-size syndrome (SFSS; P = 0.003) and early graft loss (EGL; P = 0.006). Among patients with failed modulation, donor age ≥ 45 years (hazard ratio [HR], 3.67; P = 0.02) and ABO incompatibility (HR, 3.90; P = 0.01) were independent risk factors for graft loss. Survival analysis showed that PVP > 15 mm Hg was related to poor prognosis in grafts from either ABO-incompatible or older donor age ≥ 45 years (P < 0.001), but it did not negatively affect grafts from ABO-compatible/identical and young donor age < 45 years (P = 0.27). In conclusion, intentional PVP modulation is not necessarily required in all recipients. Although grafts from both ABOcompatible/identical and young donors can tolerate PHT, lowering PVP to ≤15 mm Hg is a key to preventing SFSS and consequent EGL with grafts from either ABO-incompatible or older donors.
Original article | 1579 needed to be reconfirmed in our ALDLT series. In addition, we reported that younger donor age was an independent prognostic factor for improved recipient survival in ALDLT. (16) The importance of PVP modulation might vary according to donor age. The aim of this retrospective study was to summarize our 10-year experience of PVP modulation and to reevaluate whether it was necessary for all recipients or selected recipients in ALDLT.
Patients and Methods

stUDY pOpUlatiOn
Data were gathered from patients who underwent ALDLT at Kyoto University Hospital during the period from January 2007 to December 2016. Among the total of 353 consecutive patients, 319 were finally enrolled after excluding the following patients: 14 with prior splenectomy before transplantation, 11 with retransplantation, and 9 with incomplete PVP data resulting from technical difficulty in catheter placement in the mesenteric veins.
pvp MeasUreMent anD MODUlatiOn
Our goal was to regulate PVP to ≤15 mm Hg at the end of the operation, regardless of graft size. We did not classify patients or change our strategy according to GRWR because SFSS can occur with a GRWR range of 0.8%-1% and in rare instances in grafts with a GRWR > 1%. PVP was measured according to the method we previously reported. (17) Briefly, an 18-gauge catheter was inserted via a small jejunal vein branch to monitor the PVP. The tip of the catheter was positioned in the recipient's portal vein. The portal vein catheter was removed before abdominal closure to prevent infection. According to our PVP-modulation strategy, splenectomy was performed if the PVP remained >15 mm Hg after reperfusion. Ligation of portosystemic shunts was performed only after graft implantation, no matter whether or not PVP modulation was indicated. Only large spontaneous portosystemic shunts, such as splenorenal shunts and gastric/esophageal varices (collateral vessels), were ligated if the PVP was ≤15 mm Hg upon temporary clamping of the collaterals to improve portal flow and to prevent the portal venous steal phenomenon. (18) (19) (20) If the PVP was >15 mm Hg upon temporary clamping, the shunts were left untreated. A temporary portocaval shunt was created in some patients as necessary and then closed at the time of graft implantation. The permanent portocaval shunt procedure was used for patients with persistent PHT at the beginning of the study period, but it has since been suspended because the outcomes were unsatisfactory. Splenectomy was also performed in the following patients: (1) patients with hepatitis C virus (HCV), regardless of PVP, to prevent thrombocytopenia during the posttransplant viral treatment before direct-acting antiviral (DAA) agents were available; (2) patients with ABO incompatibility who underwent emergent ALDLT in addition to rituximab administration; and (3) patients with splenic arterial aneurysms.
iMMUnOsUppressiOn
Immunosuppressants, consisting of tacrolimus or cyclosporine and mycophenolate mofetil (MMF) in addition to low-dose steroids, were started within 24 hours after ALDLT in all patients. Until 2011, the standard immunosuppression protocol comprised tacrolimus and a low-dose steroid. (21) In 2011, the routine use of MMF together with tacrolimus began, and the use of low-dose steroids was discontinued. All ABOincompatible recipients were administered rituximab more than 2 weeks before transplantation and received MMF preoperatively except for emergent cases. (22) In emergent cases, an additional splenectomy was performed.
DeFinitiOns
The Kyushu definition of SFSS was used for the analysis, ie, the presence of both total bilirubin >10 mg/ dL at postoperative day 14 without any other definitive causes for cholestasis and a daily production of ascites of >1 L at postoperative day 14 or >500 mL at postoperative day 28. (23) Bacterial infection was identified according to the Centers for Disease Control and Prevention and National Healthcare Safety Network surveillance definitions. (24) Portal vein thrombosis (PVT) was categorized according to the Yerdel classification grade. (25) Early graft loss (EGL) was defined as retransplantation or mortality during the first 90 days after transplantation.
stUDY Design
The patients were classified into 3 groups: First, we compared the clinical backgrounds, surgical data, and postoperative outcomes among the groups. Second, we performed risk factor assessment for posttransplant graft loss in the population that had failed PVP modulation (F group). On the basis of these findings, differences in graft survival were compared according to ABO compatibility and donor age. Finally, we assessed the negative influence of splenectomy on surgical outcomes. This study was approved by the ethics committee of Kyoto University Hospital and was conducted in accordance with the Declaration of Helsinki (approval number R1388). 
statistical analYsis
Results
The patient population is summarized in Fig. 1 . In this cohort, 130 patients needed PVP modulation during ALDLT. Modulation was successful in 92 patients and failed in 38 patients. Simultaneous splenectomy was performed in 128 of the 130 patients who needed modulation; the other 2 patients, 1 with splenic artery ligation (SAL) and 1 with technical difficulty because of severe adhesion, did not undergo splenectomy. The main indications for splenectomy in the population that did not need modulation were HCV-related disease (n = 42), splenic arterial aneurysm (n = 13), ABO incompatibility (n = 3), accidental hemorrhage (n = 3), and unmentioned (n = 2). A permanent portocaval shunt between the inferior vena cava and portal vein was created in addition to splenectomy in 1 patient; a temporary shunt was created in 45 patients. The median follow-up period was 64.6 months (range, 0.3-131.0 months).
Baseline cHaracteristics
The clinical characteristics of the 3 groups are presented in Table 1 . Patients in the F group had a significantly higher prevalence of high-grade PVT (Yerdel classification grade III-IV) and had smaller grafts (GRWR < 0.8%) than other groups (P = 0.04 and P = 0.01, respectively). Other recipient and donor factors, including age, sex, background liver disease, Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, donor body weight, donor body mass index, graft type, graft weight, and ABO incompatibility, were not different among the groups. With respect to operative factors, a higher rate of splenectomy was seen in the S and F groups (P < 0.001). The cold ischemia time (CIT), warm ischemia time (WIT), and incidence of temporary portocaval shunt were very similar among the 3 groups. Immunosuppressant regimen was also not different among the groups. With respect to PVP, higher initial PVP was seen in the S and F groups (P < 0.001), and the F group was associated with significantly high PVP after reperfusion (premodulation) compared with the other groups (versus N group, P < 0.001 with the post-hoc test; versus S group, P = 0.008 with the post-hoc test).
pOsttransplant OUtcOMes
Posttransplant outcomes are also presented in Table 1 . The F group had greater blood loss (P < 0.001) and a higher volume of red blood cell transfusion (P = 0.001) than other groups. Although the incidence of acute rejection was comparable, the F group had a significantly higher incidence of SFSS (P = 0.003) and bacterial infection than the other groups, especially bacteremia (P = 0.02), as well as a higher incidence of EGL (P = 0.006). Kaplan-Meier plots in Fig. 2 show that the F group demonstrated significantly worse graft survival, compared with the S group (P = 0.005) and the N group (P = 0.005). The S group had a survival comparable with that of the N group Table 3 ). The cutoff value for donor age was determined with receiver operating characteristic (ROC) curve analysis of the association between donor age and graft loss (Supporting Fig. 1 ). This analysis showed that the largest area under the ROC curve (0.72; sensitivity = 71%, specificity = 77%) was obtained at a cutoff value of 45 years. the groups (Supporting Table 1 ). Graft survival was compared among each group according to the final status of PVP (Fig. 3A,B ). In the low-risk group, PHT did not negatively affect graft survival (100% versus 94.6% at 90 days; 100% versus 91.8% at 1 year; P = 0.27; Fig. 3A ). Meanwhile, PHT was related to poorer graft survival in the high-risk group (54.2% versus 87.7% at 90 days; 37.5% versus 78.8% at 1 year; P < 0.001; Fig. 3B ). Additionally, in the high-risk group, PHT was associated with a higher incidence of SFSS than normal PVP (50.0% [12/24] 
tHe inFlUence OF splenectOMY On sUrgical OUtcOMes
Surgical outcomes are summarized and compared between the splenectomy group (n = 128) and nonsplenectomy group (n = 128) in Table 4 . Because this study mainly focused on the outcomes of PVP modulation, the patients who underwent splenectomy for reasons other than PVP modulation (n = 63) were excluded from the analysis. The splenectomy group had longer operation time (P = 0.04), greater blood loss (P < 0.001), and higher incidence of portal or splenic vein thrombosis requiring anticoagulation therapy (P = 0.004) than the nonsplenectomy group. Other factors were comparable between the groups, including postoperative hemorrhage at the splenectomy site and infectious complications. In terms of longterm outcome, splenectomy did not increase the frequency of readmission for bacterial infection.
Discussion
Herein, we reaffirmed that intentional PVP modulation with splenectomy helped prevent SFSS and EGL with minimal surgical risks. Furthermore, we found that grafts from ABO-incompatible or older donors might benefit significantly from PVP modulation. Although short-term and longterm outcomes at our practice have generally been satisfactory, several issues require discussion.
PVP modulation was likely to fail in patients with high-grade PVT or GRWR < 0.8%, ie, high-grade PVT and smaller grafts had strong associations with persistent PHT. It is known that patients with cirrhosis have hyperdynamic circulation; dilatation of the portal vein is associated with increased blood flow. (26) The existence of PVT in addition to cirrhosis might promote a hyperdynamic state before transplantation, and this would also result in increased blood loss during transplantation. The correlation between smaller grafts and PHT has been previously Original article | 1585 discussed. (14) Interestingly, the patients with failed modulation had higher premodulation PVP after reperfusion even than those with successful modulation, suggesting that the expected pressure gradient by splenectomy has its limit. Some high-grade PVT and small grafts may induce extremely high PVP after reperfusion, which is refractory to modulation by splenectomy alone.
ABO incompatibility and older donor are wellknown risk factors in ALDLT. (16) However, the associations between PHT have rarely been described. Our data revealed that these 2 factors did not interfere with PVP modulation itself, but once the modulation failed, they led to poor prognosis by combining with PHT. ABO incompatibility is associated with a risk of acute rejection mixing cellular and humoral rejection. (27) According to the Banff criteria, histological features of acute rejection include lymphocytic infiltration in portal space and venous endothelium; the severe inflammation can elevate vascular resistance and exacerbate PHT even after the rituximab administration and splenectomy. Additionally, the most distinctive effect of aged livers is impaired liver regeneration. (28) High PVP combined with high vascular resistance (low compliance) of hepatic parenchyma in old livers may further aggravate liver regeneration. In contrast, the high compliance in young livers might reduce the burdens of PHT.
The validity of simultaneous splenectomy during ALDLT remains controversial. The positive aspects of splenectomy, in particular, preventing PHT and improving hepatic vascular compliance, have often been reported. (11, 29) However, splenectomy may negatively affect some operative outcomes, such as operative time, blood loss, PVT formation, and infectious complications. (30) The Tokyo group in Japan demonstrated an increased incidence of both reoperation for postoperative hemorrhage, mainly at the splenectomy site, and lethal infectious disease in ALDLT patients who underwent simultaneous splenectomy. (13) On the basis of those findings, the Tokyo group proposed that simultaneous splenectomy no longer be recommended in ALDLT. Similarly, the Juntendo group reported excellent graft survival (100% at 1 year) without splenectomy to modulate high PVP in left liver grafts. (31) However, differences in institutional standards for patient selection and surgical techniques may potentially confound the interpretation of outcomes. First, ABO-incompatible patients were excluded in the above-mentioned studies because the institutions never performed ABO-incompatible ALDLT. Second, the donor age was much younger in those studies than in our cohort (mean, 38 years in Tokyo and 34 years in Juntendo versus 45 years in Kyoto). Finally, no significant increase in postoperative hemorrhage at the splenectomy site or in incidence of lethal infectious disease was observed in our cohort. Therefore, it is too simplistic to exclude the necessity of PVP control with splenectomy in all ALDLT patients. At the same time, this study does not fully support the practice of simultaneous splenectomy. Recent advances in interferon-free DAAs (32) and rituximab induction (33) have made splenectomy unnecessary for HCV-positive recipients and ABO-incompatible patients. As a result, the frequency of splenectomy in the population not requiring PVP modulation has decreased from 37.3% (2007-2014) to 8.3% (after 2015) at our institution. Meanwhile, considering its procedural complexity and potential adverse effects, splenectomy should be reserved for necessary cases and alternative PVP-modulation procedures should be performed.
SAL is the simplest method to decrease PVP as an alternative to splenectomy, (34) (35) (36) but several authors described that SAL might have an insufficient and only temporary effect because of collateral formation. (14, 37) The effect of SAL on lowering PVP was reported to last for at least 14 days. (14) Considering the fact that SFSS occurs within the first 2 weeks, (10) we believe it can be an alternative to splenectomy in terms of PVP modulation. Besides, we expect the effect to increase by adding dissection of left gastroepiploic artery and gastrosplenic ligament, and these procedures are named "splenic devascularization." We are now investigating the effect of splenic devascularization instead of splenectomy prospectively.
Pharmacological therapy to reduce PVP includes vasoconstrictors and synbiotics. Both vasopressin and terlipressin are splanchnic vasoconstrictors that reduce PVP while maintaining arterial flow. (38) Their selective effects result from the fact that V1a receptors are more prevalent in portal venous circulation than in arterial circulation. Thus, the effects of vasopressin on the liver are heterogeneous and are more pronounced in the portal vein than in the hepatic artery. (39) Wagener et al. (40) reported that vasopressin injection significantly decreased PVP and the flow of native liver blood without reducing cardiac output in 16 patients undergoing liver transplantation. In an animal model, Fahrner et al. (41) reported that terlipressin injection produced a significant reduction in PVP and a concomitant improvement in liver regeneration after partial hepatectomy in mice.
Considering that more bacterial infections were observed in the group with PHT than in other groups in the present study, infection prevention is also necessary. We recently reported that PHT increases bacteremia caused by gut-specific bacteremia through the mechanism of bacterial translocation within the first few weeks after ALDLT, resulting in early mortality. (17) The role of synbiotics in preventing early infection after liver transplantation has been investigated in several randomized controlled trials. (42) (43) (44) These studies have demonstrated that synbiotic combinations are superior to prebiotics alone, (42, 43) bowel decontamination, (42) and placebo (44) in preventing early infection.
According to the current findings, we propose a new algorithm for intentional PVP modulation (Fig. 4) . In this strategy, PVP modulation will be limited to grafts from ABO-incompatible or older donors (≥45 years at our institution), and it might not be required in cases with ABO-identical/compatible and young donors, as previously reported. (13, 31) In these patients, splenic devascularization will be our first choice for reducing PVP. Splenectomy for modulation will be performed only when splenic devascularization is not sufficient. Vasoconstrictors and synbiotics should be used for those who have persistent PHT. Detailed indications, including timing, dose, and contraindications for these pharmacological therapies, need further discussion within our department. Needless to say, in the institution where the procedure for permanent portocaval Original article | 1587 shunt is established, shunt creation should also be considered. Besides, the cutoff value we set for donor age is not absolute; this may change based on prospective practice. Above all, a multidisciplinary approach must be applied to improve outcomes among patients who have potential risks for SFSS and EGL.
The present study has several limitations. First, splenectomy was performed not only for PVP modulation but also for HCV-related disease and splenic arterial aneurysm in patients for whom PVP modulation was not indicated, which is a definite confounding bias. Second, optimization of PVP alone cannot guarantee graft survival. Other factors, including the recipient's condition and donor graft quality, also affect survival. (11, 16) However, given our findings during the last 10 years, the benefits of PVP modulation cannot be denied. We believe that optimal PVP modulation after graft implantation leads to improved overall outcomes. Third, this study did not provide clear information regarding alternative procedures to splenectomy for PVP modulation; further investigation is needed regarding less invasive methods, including splenic devascularization and pharmacological treatments. Finally, most importantly, our results are not sufficient enough to explain the feasibility of our new strategy because PVP modulation had been performed for the low-risk recipients (with both young and ABOcompatible/identical grafts). Therefore, the true effect of avoiding modulation in a targeted population is still unknown. Nevertheless, as several previous reports suggested that avoiding splenectomy (or PVP modulation) may not affect graft survival in the cases with both younger and ABO-compatible/identical donors, (13, 31) we expect that these patients can tolerate PHT even without modulation. Our next step is to verify this algorithm in a prospectively accumulated cohort.
In conclusion, although PVP modulation is a safe and beneficial method for improving graft function, it is not necessarily required in all recipients. Especially with grafts from ABO-incompatible or older donors, lowering PVP to ≤15 mm Hg is a key to preventing SFSS and EGL despite graft size. Meanwhile, grafts from both ABO-compatible/identical and young donors can tolerate PHT. Further research is needed to discover more reliable and less invasive procedures for PVP modulation.
